^
BIOMARKER:

BRAF mutation

i
Other names: BRAF, B-raf proto-oncogene, B-raf proto-oncogene, Serine/threonine kinase, V-Raf murine sarcoma viral oncogene homolog B, Serine/threonine-protein kinase B-Raf, Proto-oncogene B-Raf, BRAF1, RAFB1, B-raf proto-oncogene Serine/threonine-protein kinase, Murine sarcoma viral (V-Raf) oncogene homolog B1, B-raf serine/threonine-protein, 94 KDa B-raf protein, B-RAF1
Entrez ID:
Related biomarkers:
BRAF mutation
Melanoma
dabrafenib + granisetron intravenous
Sensitive: A2 - Guideline
BRAF mutation
CRC
ramucirumab
Sensitive: B - Late Trials
BRAF mutation
CRC
ziv-aflibercept IV
Sensitive: B - Late Trials
BRAF mutation
CRC
bevacizumab
Sensitive: B - Late Trials
BRAF mutation
CRC
cetuximab
Resistant: B - Late Trials
BRAF mutation
CRC
regorafenib
Sensitive: B - Late Trials
BRAF mutation
Melanoma
nivolumab + ipilimumab
Sensitive: B - Late Trials
BRAF mutation
CRC
FOLFIRI + cetuximab
Sensitive: B - Late Trials
BRAF mutation
AML
gilteritinib
Resistant: B - Late Trials
BRAF mutation
Melanoma
PD-L1 inhibitor
Sensitive: B - Late Trials
BRAF mutation
Melanoma
ipilimumab
Sensitive: B - Late Trials
BRAF mutation
CRC
panitumumab
Sensitive: C2 – Inclusion Criteria
BRAF mutation
Melanoma
binimetinib + encorafenib
Sensitive: C2 – Inclusion Criteria
BRAF mutation
Thyroid Gland Carcinoma
selumetinib
Sensitive: C2 – Inclusion Criteria
BRAF mutation
Melanoma
BVD-523
Sensitive: C2 – Inclusion Criteria
BRAF mutation
Melanoma
trametinib
Sensitive: C2 – Inclusion Criteria
BRAF mutation
Thyroid Gland Papillary Carcinoma
trametinib + dabrafenib
Sensitive: C2 – Inclusion Criteria
BRAF mutation
Thyroid Gland Anaplastic Carcinoma
atezolizumab + cobimetinib
Sensitive: C2 – Inclusion Criteria
BRAF mutation
Colon Cancer
bevacizumab
Sensitive: C2 – Inclusion Criteria
BRAF mutation
Melanoma
selumetinib
Sensitive: C2 – Inclusion Criteria
BRAF mutation
Melanoma
nivolumab + trametinib + dabrafenib
Sensitive: C2 – Inclusion Criteria
BRAF mutation
Thyroid Gland Papillary Carcinoma
vemurafenib
Sensitive: C2 – Inclusion Criteria
BRAF mutation
Melanoma
nivolumab
Sensitive: C2 – Inclusion Criteria
BRAF mutation
NSCLC
PD-L1 inhibitor
Sensitive: C3 – Early Trials
BRAF mutation
NSCLC
PD1 inhibitor
Sensitive: C3 – Early Trials
BRAF mutation
Melanoma
Immunotherapy
Resistant: C3 – Early Trials
BRAF mutation
Ovarian Cancer
PLX8394
Sensitive: C3 – Early Trials
BRAF mutation
Mucosal Melanoma
PD1 inhibitor
Sensitive: C3 – Early Trials
BRAF mutation
Melanoma
dabrafenib + KRT-232
Sensitive: C3 – Early Trials
BRAF mutation
Melanoma
trametinib + dabrafenib + durvalumab
Sensitive: C3 – Early Trials
BRAF mutation
Melanoma
AS703026
Sensitive: C3 – Early Trials
BRAF mutation
Solid Tumor
Immunotherapy
Resistant: C3 – Early Trials
BRAF mutation
Multiple Myeloma
venetoclax + cobimetinib
Sensitive: C3 – Early Trials
BRAF mutation
Ovarian Cancer
vemurafenib + sorafenib
Sensitive: C3 – Early Trials
BRAF mutation
Melanoma
crizotinib + vemurafenib
Sensitive: C3 – Early Trials
BRAF mutation
Melanoma
PLX8394 + cobicistat
Sensitive: C3 – Early Trials
BRAF mutation
CRC
PLX8394 + cobicistat
Sensitive: C3 – Early Trials
BRAF mutation
Thyroid Gland Anaplastic Carcinoma
PLX8394 + cobicistat
Sensitive: C3 – Early Trials
BRAF mutation
Thyroid Gland Papillary Carcinoma
PLX8394 + cobicistat
Sensitive: C3 – Early Trials
BRAF mutation
Glioma
PLX8394 + cobicistat
Sensitive: C3 – Early Trials
BRAF mutation
Melanoma
BRAF inhibitor
Sensitive: C3 – Early Trials
BRAF mutation
Cutaneous Melanoma
PD1 inhibitor
Resistant: C3 – Early Trials
BRAF mutation
CRC
EGFR inhibitor
Resistant: C3 – Early Trials
BRAF mutation
Ovarian Cancer
VS-6766
Sensitive: C3 – Early Trials
BRAF mutation
Melanoma
dabrafenib + SNR1611
Sensitive: C3 – Early Trials
BRAF mutation
Melanoma
trametinib + KRT-232
Sensitive: C3 – Early Trials
BRAF mutation
Melanoma
selumetinib + RTB101
Sensitive: C3 – Early Trials
BRAF mutation
Melanoma
DAY101
Sensitive: C3 – Early Trials
BRAF mutation
Thyroid Gland Papillary Carcinoma
dabrafenib
Sensitive: C3 – Early Trials
BRAF mutation
Thyroid Gland Anaplastic Carcinoma
vemurafenib + atezolizumab
Sensitive: C3 – Early Trials
BRAF mutation
CRC
cetuximab + selumetinib
Sensitive: C3 – Early Trials
BRAF mutation
NSCLC
Immunotherapy
Sensitive: C3 – Early Trials
BRAF mutation
Multiple Myeloma
MEK inhibitor
Sensitive: C3 – Early Trials
BRAF mutation
Melanoma
pembrolizumab + INCB024360
Sensitive: C3 – Early Trials
BRAF mutation
Melanoma
BRAF inhibitor + MEK inhibitor
Sensitive: C3 – Early Trials
BRAF mutation
Mucosal Melanoma
cisplatin + dacarbazine
Sensitive: C3 – Early Trials
BRAF mutation
NSCLC
trametinib + dabrafenib
Sensitive: C3 – Early Trials
BRAF mutation
Mucosal Melanoma
cisplatin + temozolomide
Sensitive: C3 – Early Trials
BRAF mutation
NSCLC
durvalumab
Resistant: C3 – Early Trials
BRAF mutation
Melanoma
PD1 inhibitor + CTLA4 inhibitor
Sensitive: C3 – Early Trials
BRAF mutation
Prostate Cancer
enzalutamide
Resistant: C3 – Early Trials
BRAF mutation
CRC
trametinib + dabrafenib + panitumumab
Sensitive: C3 – Early Trials
BRAF mutation
CRC
cetuximab + encorafenib
Sensitive: C3 – Early Trials
BRAF mutation
Thyroid Gland Anaplastic Carcinoma
trametinib + dabrafenib
Sensitive: C3 – Early Trials
BRAF mutation
NSCLC
cobimetinib + HM95573
Sensitive: C3 – Early Trials
BRAF mutation
Melanoma
cobimetinib + HM95573
Sensitive: C3 – Early Trials
BRAF mutation
Melanoma
PD1 inhibitor + BRAF inhibitor
Sensitive: C3 – Early Trials
BMC Cancer - 4 weeks
BRAF mutation
Melanoma
PD1 inhibitor + BRAF inhibitor + MEK inhibitor
Sensitive: C3 – Early Trials
BMC Cancer - 4 weeks
BRAF mutation
Melanoma
EOS-448
Sensitive: C4 – Case Studies
BRAF mutation
LUAD
crizotinib + vemurafenib
Sensitive: C4 – Case Studies
BRAF mutation
Cutaneous Melanoma
BRAF inhibitor
Resistant: C4 – Case Studies
BRAF mutation
Cutaneous Melanoma
BRAF inhibitor + MEK inhibitor
Sensitive: C4 – Case Studies
BRAF mutation
Cholangiocarcinoma
LTT462
Sensitive: C4 – Case Studies
BRAF mutation
Cholangiocarcinoma
BRAF inhibitor
Sensitive: C4 – Case Studies
BRAF mutation
RCC
vemurafenib
Sensitive: C4 – Case Studies
BRAF mutation
CRC
trametinib + dabrafenib + panitumumab
Resistant: C4 – Case Studies
BRAF mutation
Anaplastic Astrocytoma
dabrafenib
Sensitive: C4 – Case Studies
BRAF mutation
Thyroid Gland Anaplastic Carcinoma
dabrafenib + SCH772984
Sensitive: D – Preclinical
BRAF mutation
Melanoma
ARN22089
Sensitive: D – Preclinical
BRAF mutation
Breast Cancer
CB-228
Sensitive: D – Preclinical
BRAF mutation
CRC
PLX4720
Sensitive: D – Preclinical
BRAF mutation
Pancreatic Cancer
SCH772984
Sensitive: D – Preclinical
BRAF mutation
Melanoma
SCH772984
Sensitive: D – Preclinical
BRAF mutation
Melanoma
PLX4720
Sensitive: D – Preclinical
BRAF mutation
NSCLC
LY3009120
Sensitive: D – Preclinical
BRAF mutation
CRC
SY-5609
Sensitive: D – Preclinical
BRAF mutation
CRC
ABT 263 + AZD8055
Sensitive: D – Preclinical
BRAF mutation
Ovarian Cancer
CI-1040
Sensitive: D – Preclinical
BRAF mutation
Melanoma
vemurafenib + dabrafenib + encorafenib
Sensitive: D – Preclinical
BRAF mutation
Thyroid Gland Carcinoma
SU6656
Sensitive: D – Preclinical
BRAF mutation
Thyroid Gland Papillary Carcinoma
PP2
Sensitive: D – Preclinical
BRAF mutation
Thyroid Gland Medullary Carcinoma
RTB101 + RAF265
Sensitive: D – Preclinical